Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2376239 | 0.81 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL7056902 | 0.80 | ENPP2 (0.52) | ENPP2PTGS2MAPTSMN1; SMN2 | |
| SCHEMBL8328140 | 0.78 | ENPP2 (0.50) | ENPP2PTGS2MAPTSMN1; SMN2 | |
| SCHEMBL8328143 | 0.78 | ENPP2 (0.50) | ENPP2PTGS2MAPTSMN1; SMN2 | |
| SCHEMBL16712211 | 0.77 | ALDH1A1 (0.41) | ALDH1A1HSD17B10TP53TSHRMAPK1 | |
| SCHEMBL3872941 | 0.75 | POLB (0.59) | ALDH1A1HSD17B10TP53TSHRMAPK1 | |
| SCHEMBL13632324 | 0.75 | ALDH1A1 (0.39) | ALDH1A1HSD17B10TP53TSHRMAPK1 | |
| SCHEMBL11921694 | 0.75 | ALDH1A1 (0.50) | ALDH1A1HSD17B10TP53TSHRMAPK1 | |
| SCHEMBL20904148 | 0.75 | CA2 (0.61) | TSHRPTGS2 | |
| SCHEMBL3044709 | 0.75 | CYP3A4 (0.48) | ENPP2TSHRMAPK1PTGS2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| EP-1844020-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | Exelixis, Inc. (US) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006076202-A1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS | EXELIXIS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | ENPP2 377/4885ALDH1A1 852/4885HSD17B10 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.